From Megan Deeter

May 15, 2024

Cincinnati, OH (May 15, 2024) – OHC, through its affiliation with The US Oncology Network (The Network), announced a collaboration with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials. Since its inception, SCRI has conducted nearly 750 first-in-human trials and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. SCRI at OHC will provide adults facing cancer additional opportunities to pursue enrollment into the latest research trials examining novel therapies.

Medical oncologist, hematologist, and OHC President D. Randolph Drosick, MD, states, “SCRI has a long history of advancing therapies through clinical research, with more than 1,000 trials currently enrolling. Today’s trials are tomorrow’s treatment options. Patients who participate in research are shaping the future of cancer care.”

The collaboration with SCRI offers numerous advantages for cancer patients:

  • Greater Treatment Options: Eligible patients will have access to a wider range of clinical trials, offering options based on their individualized treatment plan.
  • Access to Cutting-Edge Therapies: Eligible patients will have the opportunity to participate in trials evaluating the latest advancements in cancer research.
  • Offering Hope: Participation in clinical trials can provide access to promising new therapies that may improve a patient’s prognosis and quality of life.
  • Staying at the Forefront: OHC is transforming cancer care by offering patients the most up-to-date treatment options while supporting the region’s medical providers through expert research care referrals.
  • Clinical trial matching technology: OHC has access to Genospace, a highly specific trial matching and data science technology that works with SCRI’s Personalized Medicine team to alert providers of a patient’s eligibility for a clinical trial.

OHC is the only independent, physician-led adult cancer practice with 27 cancer specialists and 20 advanced practice providers delivering superior, comprehensive oncology care at eight convenient locations in Cincinnati. The OHC care team also includes nurse and financial navigators, and cancer genetic and supportive care specialists. This multi-disciplinary team provides access to innovative approaches to cancer while providing a range of services including emotional, financial, and social support to help patients gain power over cancer’s impact on their lives.

“SCRI shares a commitment with OHC to offer novel therapies in the community,” said Dee Anna Smith, CEO of SCRI. “Through our collaboration, we are bringing together exceptional local physician expertise with internationally-recognized research teams to advance therapies and expand access to clinical trials for people facing cancer throughout the Cincinnati region.”

This relationship between OHC and SCRI highlights OHC’s unwavering commitment to providing the most advanced cancer care possible. By offering cancer patients the opportunity to pursue the latest clinical trials, OHC offers patients hope and the option to choose leading-edge cancer therapies, close to home.

About OHC

OHC (Oncology Hematology Care), a practice in The US Oncology Network, has been fighting cancer on the front lines for more than 40 years. We are the region’s leading experts in treating nearly every form of adult cancer and complex blood disorder. OHC cancer experts include medical oncologists, hematologists, blood and marrow transplant specialists, cellular therapy specialists, radiation oncologists, gynecologic oncologists, and breast surgical oncologists. OHC continues to bring hope and leading-edge treatment options through its collaboration with Sarah Cannon Research Institute (SCRI), one of the world’s leading cancer research organizations conducting community-based clinical trials and whose work has led to the majority of new cancer therapies approved by the FDA today. OHC is the region’s first, most experienced, and only certified independent adult cancer practice to offer revolutionary treatments like CAR-T cellular therapy, NK cell therapy, and BiTE therapy for adults, ushering in a new frontier in the fight against cancer. At its heart, our approach to cancer care is simple — to surround you with everything you need so you can focus on what matters most: beating cancer. For more information about OHC, or a second opinion, call 1-888-649-4800 or visit ohcare.com.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *